文献速递血栓与止血

癌症相关孤立性远端深静脉血栓的长期结局:OPTIMEV研究

Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study.
PubMed 文献 · J Thromb Haemost · 2017-04-21

基于前瞻性多中心观察性OPTIMEV队列,比较癌症相关孤立性远端深静脉血栓(iDDVT)患者与年龄性别匹配的癌症相关孤立性近端DVT患者(1:1)及无癌症iDDVT患者(1:2)3年内死亡、VTE复发和大出血的发生率。癌症相关iDDVT患者预后与癌症相关近端DVT相似,而明显差于无癌症的iDDVT患者。

要点

  • 癌症相关iDDVT患者3年死亡风险与癌症相关孤立性近端DVT患者相似(aHR=1.0)。
  • 癌症相关iDDVT患者死亡风险约为无癌症iDDVT患者的9倍(aHR=9.3)。
  • 癌症相关iDDVT患者VTE复发风险高于无癌症iDDVT患者(aCHR=2.0)。

核心结论

  • 癌症相关iDDVT患者的预后似乎与癌症相关孤立性近端DVT患者相似,而明显差于无癌症的iDDVT患者,提示癌症相关iDDVT具有较高的临床意义并需要进一步研究。

研究设计与样本

  • 基于观察性、前瞻性、多中心OPTIMEV队列数据,比较3年内死亡、VTE复发和大出血发生率。
  • 癌症相关iDDVT组与癌症相关孤立性近端DVT组按年龄和性别1:1匹配(各92例)。
  • 癌症相关iDDVT组与无癌症iDDVT组按年龄和性别1:2匹配(92例 vs 184例)。

主要发现

  • 癌症相关iDDVT组(n=92)vs 癌症相关孤立性近端DVT组(n=92):死亡40.8%每人年 vs 38.3%每人年(aHR=1.0,95%CI 0.7-1.4)。
  • 癌症相关iDDVT组 vs 癌症相关孤立性近端DVT组:大出血3.8%每人年 vs 3.6%每人年(aCHR=0.9,95%CI 0.3-3.2)。
  • 癌症相关iDDVT组 vs 癌症相关孤立性近端DVT组:VTE复发5.4%每人年 vs 11.5%每人年(aCHR=1.8,95%CI 0.7-4.5)。
  • 癌症相关iDDVT组 vs 无癌症iDDVT组(n=184):死亡38.3%每人年 vs 3.5%每人年(aHR=9.3,95%CI 5.5-15.9)。
  • 癌症相关iDDVT组 vs 无癌症iDDVT组:大出血3.6%每人年 vs 1.8%每人年(aCHR=2.0,95%CI 0.6-6.1);VTE复发11.5%每人年 vs 5.0%每人年(aCHR=2.0,95%CI 1.0-3.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要进一步研究(need for additional studies)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Clinical significance of cancer-related isolated distal deep vein thrombosis (iDDVT) is unknown. We studied patients with iDDVT, with and without cancer, and proximal DVT with cancer. Cancer-related iDDVT patients have a much poorer prognosis than iDDVT patients without cancer. Cancer-related iDDVT patients have a similar prognosis to cancer-related proximal DVT patients. SUMMARY: Background Isolated distal deep vein thrombosis (iDDVT) (infra-popliteal DVT without pulmonary embolism [PE]) is a frequent event and, in the absence of cancer, is usually considered to be a minor form of venous thromboembolism (VTE). However, the clinical significance of cancer-related iDDVT is unknown. Methods Using data from the observational, prospective multicenter OPTIMEV cohort, we compared, at 3 years, the incidences of death, VTE recurrence and major bleeding in patients with cancer-related iDDVT with those in cancer patients with isolated proximal DVT (matched 1:1 on age and sex) and patients with iDDVT without cancer (matched 1:2 on age and sex). Results As compared with patients with cancer-related isolated proximal DVT (n = 92), those with cancer-related iDDVT (n = 92) had a similar risk of death (40.8% per patient-year (PY) vs. 38.3% per PY; aHR = 1.0, 95% CI[0.7-1.4]) and of major bleeding (3.8% per PY vs. 3.6% per PY, aCHR = 0.9 [0.3-3.2]) and a higher risk of VTE recurrence (5.4% per PY vs. 11.5% per PY; aCHR = 1.8 [0.7-4.5]). As compared with patients with iDDVT without cancer (n = 184), those with cancer-related iDDVT had a nine times higher risk of death (3.5% per PY vs. 38.3% per PY; aHR = 9.3 [5.5-15.9]), a higher risk of major bleeding (1.8% per PY vs. 3.6% per PY; aCHR = 2.0 [0.6-6.1]) and a higher risk of VTE recurrence (5.0% per PY vs. 11.5% per PY; aCHR = 2.0 [1.0-3.7]). The results remained similar in the subgroup of patients without history of VTE. Conclusion Patients with cancer-related iDDVT seem to have a prognosis that is similar to that of patients with cancer-related isolated proximal DVT and a dramatically poorer prognosis than patients with iDDVT without cancer. This underlines the high clinical significance of cancer-related iDDVT and the need for additional studies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Galanaud JP, Sevestre MA, Pernod G, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost. 2017. PMID: 28266773. doi:10.1111/jth.13664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。